Atrayee Basu Mallick1, Sant P Chawla2. 1. Department of Medical Oncology, Thomas Jefferson University Hospital, 1025 Walnut Street, Suite 700, Philadelphia, PA, 19107, USA. Atrayee.basumallick@jefferson.edu. 2. Sarcoma Oncology Center, 2811 Wilshire Blvd, Santa Monica, CA, 90403, USA.
Abstract
PURPOSE OF REVIEW: To highlight the new developments in the management of advanced giant cell tumor of bone, a rare locally aggressive benign tumor, which was traditionally managed with surgery alone by either curettage and local adjuvant therapy, wide resection, or marginal excision. Here, we review the current role of systemic therapy for management of locally advanced or metastatic giant cell tumor of bone (GCTB). RECENT FINDINGS: The elucidation of the pathophysiology of giant cell tumor of bone, especially with regards to the role of nuclear factor kappa B ligand (RANKL), has led to the Food and Drug Administration (FDA) approval of denosumab in the management of locally advanced or metastatic GCTB. For advanced giant cell tumor where surgical resection alone can cause severe morbidity, the paradigm has shifted from local treatment alone to multidisciplinary management with the consideration of use of denosumab.
PURPOSE OF REVIEW: To highlight the new developments in the management of advanced giant cell tumor of bone, a rare locally aggressive benign tumor, which was traditionally managed with surgery alone by either curettage and local adjuvant therapy, wide resection, or marginal excision. Here, we review the current role of systemic therapy for management of locally advanced or metastatic giant cell tumor of bone (GCTB). RECENT FINDINGS: The elucidation of the pathophysiology of giant cell tumor of bone, especially with regards to the role of nuclear factor kappa B ligand (RANKL), has led to the Food and Drug Administration (FDA) approval of denosumab in the management of locally advanced or metastatic GCTB. For advanced giant cell tumor where surgical resection alone can cause severe morbidity, the paradigm has shifted from local treatment alone to multidisciplinary management with the consideration of use of denosumab.
Entities:
Keywords:
Denosumab; GCT; GCTB; Giant cell tumor of bone; Osteoclastoma; RANK L
Authors: David L Lacey; William J Boyle; W Scott Simonet; Paul J Kostenuik; William C Dougall; John K Sullivan; Javier San Martin; Roger Dansey Journal: Nat Rev Drug Discov Date: 2012-05 Impact factor: 84.694
Authors: Leticia Del Carmen Baena-Ocampo; Esperanza Ramirez-Perez; Luis Miguel Linares-Gonzalez; Ricardo Delgado-Chavez Journal: Ann Diagn Pathol Date: 2008-09-09 Impact factor: 2.090
Authors: Maurice Balke; Laura Campanacci; Carsten Gebert; Piero Picci; Max Gibbons; Richard Taylor; Pancras Hogendoorn; Judith Kroep; John Wass; Nicholas Athanasou Journal: BMC Cancer Date: 2010-08-29 Impact factor: 4.430
Authors: Vincenzo Nasca; Anna Maria Frezza; Carlo Morosi; Ciriaco Buonomenna; Antonina Parafioriti; Giorgio Zappalà; Federica Bini; Paolo Giovanni Casali; Mattia Loppini; Silvia Stacchiotti Journal: Front Oncol Date: 2022-07-19 Impact factor: 5.738